Danny Rischin

9PUBLICATIONS
97CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 22, 2025
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Danny Rischin, Aaron R Hansen, Ezra E W Cohen

|Aug 27, 2025
Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma.

Annette M Lim, Sandro Porceddu, Danny Rischin

|Aug 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors.

Michele Maio, Victor Moreno, Juan Martin-Liberal

|May 22, 2025
Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.

Benedict J Panizza, Stephen John O'Leary, Christopher David Hart

|Apr 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Jérôme Fayette, Lisa Licitra, Kevin Harrington

|Mar 12, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.

Danny Rischin, Brett G M Hughes, Nicole Basset-Séguin

Pageof 2

Frequent Collaborators

2 joint publications

Kevin J Harrington

2 joint publications

Robert L Ferris

2 joint publications

Annette M Lim

2 joint publications

Robert I Haddad